Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 6Gliosarcoma 6Glioblastoma 6Endometrial Neoplasms 6Carcinoma, Renal Cell 6Sarcoma 5Brain Neoplasms 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Rhabdomyosarcoma 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Glioma 3Breast Neoplasms 3Unspecified Childhood Solid Tumor, Protocol Specific 2Unspecified Adult Solid Tumor, Protocol Specific 2Ovarian Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma 2

Interventions

Trastuzumab 12Paclitaxel 10Taxes 9Doxorubicin 7Cyclophosphamide 7Docetaxel 6Bevacizumab 6Lapatinib 5Filgrastim 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5Vorinostat 4tipifarnib 3pegfilgrastim 3cediranib 3Peripheral Blood Stem Cell Transplantation 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Carboplatin 3Capecitabine 3veliparib 2ixabepilone 2entinostat 2alvocidib 2Tamoxifen 2Radiotherapy 2Neoadjuvant Therapy 2MK 2206 2Interleukin-12 Subunit p35 2Interleukin-12 2Immunoenzyme Techniques 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Neoplasms, Male × temsirolimus × Clear all
NCT00699491 2018-06-13

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
48 enrolled 14 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡